Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl 3-(3-Indolylmethyl)Propanoate SCHEMBL290808 | 0.89 | MAPT (0.71) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL12371556 | 0.89 | MAPT (0.78) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL12836579 | 0.86 | MEN1 (0.73) | MAPTGAAMEN1KMT2AGFER | |
| SCHEMBL1358575 | 0.84 | CYP1A2 (0.76) | MAPTALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL8998855 | 0.83 | MAPT (0.72) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL29634969 | 0.83 | MAPT (0.72) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL9148446 | 0.83 | CYP1A2 (0.70) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL9152556 | 0.82 | CYP1A2 (0.68) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL6275395 | 0.81 | ALDH1A1 (0.74) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL20441327 | 0.81 | HTR2A (0.62) | MAPTALDH1A1MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740208-B1 | COMPOUNDS FOR TREATING RAC-GTPASE MEDIATED DISORDER | CHILDRENS MEDICAL CENTER (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3740208-B1 | COMPOUNDS FOR TREATING RAC-GTPASE MEDIATED DISORDER | CHILDRENS MEDICAL CENTER (US) | 2023-10-25 | — | — | EP | disclosed |
| US-11685733-B2 | Compounds for treating Rac-GTPase mediated disorder | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685733-B2 | Compounds for treating Rac-GTPase mediated disorder | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685733-B2 | Compounds for treating Rac-GTPase mediated disorder | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3740208-A1 | COMPOUNDS FOR TREATING RAC-GTPASE MEDIATED DISORDER | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-11-25 | — | — | EP | disclosed |
| US-20200347044-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | CHILDREN'S MEDICAL CENTER CORPORATION | 2020-11-05 | — | — | US | disclosed |
| US-20200347044-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | CHILDREN'S MEDICAL CENTER CORPORATION | 2020-11-05 | — | — | US | disclosed |
| WO-2019143833-A1 | COMPOUNDS FOR TREATING RAC-GTPASE MEDIATED DISORDER | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-07-25 | — | — | WO | disclosed |
| WO-2019143833-A1 | COMPOUNDS FOR TREATING RAC-GTPASE MEDIATED DISORDER | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685733-B2 | Compounds for treating Rac-GTPase mediated disorder | ARHGDIB, ARHGEF2, ARHGDIA | MAPT 3225/4885ALDH1A1 3084/4885GAA 911/4885 |
| US-20200347044-A1 | Compounds for Treating Rac-GTPase Mediated Disorder | ARHGDIB, ARHGEF2, ARHGDIA | MAPT 3225/4885ALDH1A1 3084/4885GAA 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.